Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
BMS-986484 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Part 1A: BMS-986484 Dose Escalation | EXPERIMENTAL | - |
| Part 1B: BMS-986484 + Nivolumab Dose Escalation | EXPERIMENTAL | - |
| Part 2A: BMS-986484 Dose Expansion | EXPERIMENTAL | - |
| Part 2B: BMS-986484 + Nivolumab Dose Expansion | EXPERIMENTAL | - |
| Part 1C: BMS-986484 + Nivolumab + Chemotherapy Dose Escalation | EXPERIMENTAL | - |
| Part 1 Co-Admin: BMS-986484 + Nivolumab | EXPERIMENTAL | - |
| Part 1SC: BMS-986484 Monotherapy Subcutaneous Dose Escalation | EXPERIMENTAL | - |
| Part 2C: BMS-986484 + Nivolumab + Chemotherapy Dose Expansion | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| BMS-986484 | DRUG | Specified dose on specified days |
| Nivolumab | BIOLOGICAL | Specified dose on specified days |
| Oxaliplatin | DRUG | Specified dose on specified days |
| Capecitabine | DRUG | Specified dose on specified days |
| Fluorouracil | DRUG | Specified dose on specified days |
| Calcium folinate | DRUG | Specified dose on specified days |
Inclusion Criteria: * Locally advanced unresectable, metastatic, or recurrent malignant tumors including non-small cell lung cancer (NSCLC), pancreatic ductal adenocarcinoma (PDAC), gastric/gastroesophageal junction adenocarcinoma (G/GEJC), microsatellite stable colorectal cancer (MSS CRC), and squ...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 2 | PHASE2 | pembrolizumab |
| Incyte Corporation | INCY | 1 | PHASE2 | Chemotherapy, Retifanlimab |
| Iovance Biotherapeutics Inc | IOVA | 2 | PHASE2 | E7 TCR-T cells, Aldesleukin |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE1 | KFA115, pembrolizumab |
| AstraZeneca PLC | AZN | 1 | - | Trastuzumab deruxtecan |
BMS-986484 is an investigational small molecule being studied for the treatment of advanced solid tumors. It is currently in Phase 1 clinical development, meaning it has not yet been approved by regulatory authorities and is still being evaluated for safety and efficacy in clinical trials.
BMS-986484 is being developed by Bristol-Myers Squibb Company, a global biopharmaceutical company. Bristol-Myers Squibb trades on the New York Stock Exchange under the ticker symbol BMY.
BMS-986484 is in Phase 1 clinical development. It is an investigational drug and has not been approved by the FDA or any other regulatory agency. The drug is being studied in a Phase 1 trial for advanced solid tumors.
BMS-986484 is being evaluated in a Phase 1 clinical trial with the identifier NCT06544655. This study is investigating BMS-986484 alone and in combination therapy in participants with advanced solid tumors. The trial is active but not recruiting and has an estimated enrollment of 213 participants.
The specific molecular target of BMS-986484 has not been disclosed in the available information. As a small molecule, it is designed to interact with cellular pathways involved in tumor growth, but the exact mechanism of action is not publicly detailed at this time.